# Kyoto University Hospital

Source: https://onco.cc/institutions/kyoto-university-hospital/  
OnCo record `kyoto-university-hospital` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The university where Tasuku Honjo discovered PD-1 and Shinya Yamanaka created iPS cells; its hospital leads Japanese immunotherapy and cell therapy research.

## Summary

Kyoto University Hospital is the clinical arm of a university whose Graduate School of Medicine produced two Nobel prizes relevant to cancer: Tasuku Honjo's discovery of PD-1 (2018 Nobel), which led to nivolumab, and Shinya Yamanaka's induced pluripotent stem cells (2012 Nobel), now the basis of iPS-derived NK and T-cell products from the Center for iPS Cell Research and Application. The hospital runs Japan's largest early-phase immunotherapy programme with Ono Pharmaceutical partnerships, a leading haematology and transplant department, hepatobiliary and pancreatic surgery, and a core institution role in JCOG and WJOG trials. Its Institute for Advancement of Clinical and Translational Science supports investigator-initiated trials, and Kyoto's cancer research includes the Kyoto Prize-associated work on immune checkpoint biology.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: 京都大学医学部附属病院; Kyoto University Cancer Center
- City: Kyoto, JP
- Type: hospital
- Website: https://www.kuhp.kyoto-u.ac.jp

## Sources

- Kyoto University Hospital: https://www.kuhp.kyoto-u.ac.jp
- Center for iPS Cell Research and Application: https://www.cira.kyoto-u.ac.jp
- Kyoto University Graduate School of Medicine: https://www.med.kyoto-u.ac.jp

## Connected records

- collections: [Japanese oncology guidelines (JSMO, JSCO and organ societies)](https://onco.cc/collections/jsmo-jsco-guidelines/)
- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [CAR-NK & CAR-macrophage](https://onco.cc/technologies/car-nk-macrophage/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/), [PD-L1](https://onco.cc/targets/pdl1/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Japan Clinical Oncology Group (JCOG)](https://onco.cc/companies/jcog/)
- people: [Akifumi Takaori](https://onco.cc/people/akifumi-takaori/), [Tasuku Honjo](https://onco.cc/people/tasuku-honjo/)

---
JSON: https://onco.cc/api/v1/entities/kyoto-university-hospital.json